A Randomized, Double Blind Clinical Trial to Assess Safety, Tolerability and Pharmacokinetics of MK-1708 in Healthy Elderly Participants
Latest Information Update: 05 Nov 2024
At a glance
- Drugs MK 1708 (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 30 Oct 2024 Planned End Date changed from 18 Apr 2025 to 14 Mar 2025.
- 30 Oct 2024 Planned primary completion date changed from 18 Apr 2025 to 14 Mar 2025.
- 24 Oct 2024 New trial record